Vion Pharmaceuticals [clinicaltrials_resource:0d7383a3e02523ea6a1b383b4c62156f]
collaborator [clinicaltrials_vocabulary:collaborator]
3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors [clinicaltrials:NCT00004213]VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy [clinicaltrials:NCT00004216]3-AP in Treating Patients With Advanced Cancer [clinicaltrials:NCT00006218]VNP20009 in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00006254]3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer [clinicaltrials:NCT00016874]Combination Chemotherapy in Treating Patients With Advanced Cancer [clinicaltrials:NCT00024323]VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas [clinicaltrials:NCT00025129]VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome [clinicaltrials:NCT00049686]VNP40101M in Treating Patients With Advanced or Metastatic Cancer [clinicaltrials:NCT00049699]3-AP in Treating Patients With Advanced Prostate Cancer [clinicaltrials:NCT00054015]3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer [clinicaltrials:NCT00064051]3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer [clinicaltrials:NCT00064064]3-AP and Cytarabine in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00064090]VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies [clinicaltrials:NCT00070538]VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia [clinicaltrials:NCT00083187]Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias [clinicaltrials:NCT00098436]clinicaltrials:NCT00112554VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer [clinicaltrials:NCT00282022]VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders [clinicaltrials:NCT00304005]VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia [clinicaltrials:NCT00354276]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
Vion Pharmaceuticals [clinicaltrials_resource:0d7383a3e02523ea6a1b383b4c62156f]
Bio2RDF identifier
0d7383a3e02523ea6a1b383b4c62156f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0d7383a3e02523ea6a1b383b4c62156f
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:0d7383a3e02523ea6a1b383b4c62156f
title
Vion Pharmaceuticals
@en
type
label
Vion Pharmaceuticals [clinicaltrials_resource:0d7383a3e02523ea6a1b383b4c62156f]
@en